Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Highlights ► PI3Kδ and PI3Kγ have non-redundant and often co-ordinated roles in immune cell function. ► Increasing appreciation of a role for PI3Kβ in the immune system. ► Inhibitors of PI3Kδ isoform have proven successful for treatment of B cell malignancies. ► The lipid phosphatase SHIP-1 offers a...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2012-08, Vol.12 (4), p.444-451
Main Authors: Blunt, Matthew D, Ward, Stephen G
Format: Article
Language:English
Subjects:
Animals
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Humans
Inflammation - drug therapy
Inflammation - immunology
Inositol Polyphosphate 5-Phosphatases
Internal Medicine
Isoenzymes - antagonists & inhibitors
Isoenzymes - immunology
Leukemia - drug therapy
Leukemia - immunology
Medical Education
Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Phosphatidylinositol 3-Kinases - immunology
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases
Phosphoric Monoester Hydrolases - antagonists & inhibitors
Phosphoric Monoester Hydrolases - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► PI3Kδ and PI3Kγ have non-redundant and often co-ordinated roles in immune cell function. ► Increasing appreciation of a role for PI3Kβ in the immune system. ► Inhibitors of PI3Kδ isoform have proven successful for treatment of B cell malignancies. ► The lipid phosphatase SHIP-1 offers a novel opportunity to manipulate PI3K-dependent signaling in the immune system. ► Both small molecule activators and inhibitors of SHIP-1 have been reported and show efficacy as anti-leukemic drugs.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2012.02.015